Delivery Order SPE2DR25D3103-SPE2DR26F9N03
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 11, 2025, for the supply of BARHEMSYS 10 mg/4 ml vials with a ceiling value of $1,285.79. This competitively awarded, firm fixed-price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract carries an ultimate completion date...
- The Defense Logistics Agency awarded a $5,094.17 delivery order to AmerisourceBergen Drug Corp for Barhemsys 5 mg/2 ml vials on November 5, 2025, with completion scheduled for November 6, 2025. This firm fixed price, competitively awarded contract represents a single pharmaceutical supply transaction with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and is performing under its existing...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,024.38 firm fixed-price delivery order is for the supply of the medication BARHEMSYS 5 MG/2 ML VIAL 2ML. The contract has an ultimate completion date of August 29, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as a...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $9,867.20 by the Defense Logistics Agency's Medical Supply Chain on December 10, 2025, with an ultimate completion date of December 11, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $4,296.85 by the Defense Logistics Agency's Medical Supply Chain on November 3, 2025, with an ultimate completion date of November 4, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which is valued at $999,999,999.00 and extends through December 2026. The award...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $7,943.01 by the Defense Logistics Agency's Medical Supply Chain on December 6, 2025, with an ultimate completion date of December 8, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The vendor, headquartered in Conshohocken, Pennsylvania, is a...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $7,838.53 by the Defense Logistics Agency's Medical Supply Chain on December 8, 2025. This competitive, non-set-aside contract is structured as a firm fixed-price delivery order with an ultimate completion date of December 9, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $10,447.93 by the Defense Logistics Agency's Medical Supply Chain on August 18, 2025. This firm fixed-price delivery order, with an ultimate completion date of August 19, 2025, represents a competitively awarded, non-set-aside contract. The award is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $7,070.18 by the Defense Logistics Agency's Medical Supply Chain on December 8, 2025, with an ultimate completion date of December 9, 2025. This competitive award, issued without a set-aside designation, is structured as a firm fixed-price delivery order. The contract represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a delivery order award valued at $1,627.80 from the Defense Logistics Agency's Medical Supply Chain on November 5, 2025, with an ultimate completion date of November 6, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and...
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F9N03Delivery Order
AmerisourceBergen Drug Corp was awarded a $7,385.19 delivery order by the Defense Logistics Agency (DLA) on December 9, 2025, for the supply of Barhemsys 10 mg/4 mL vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of December 10, 2025, and performance directed to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. This award is part of AmerisourceBergen's strategic role as a pharmaceutical prime vendor supporting federal medical procurement across military and veteran healthcare systems. As a major pharmaceutical distributor, AmerisourceBergen maintains an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies distributed through the DLA Medical Supply Chain. The company's competitive positioning in the federal marketplace is demonstrated through its consistent receipt of non-set-aside awards and its designation as a child contract under the larger SPE2DX prime indefinite delivery vehicle, which enables flexible pharmaceutical support to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.4k | 12/8/25 |